Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model

Monica Rodolfo, Carolina Salvi, Cinzia Bassi, Giorgio Parmiani

Research output: Contribution to journalArticlepeer-review

Abstract

We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P

Original languageEnglish
Pages (from-to)28-36
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1990

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model'. Together they form a unique fingerprint.

Cite this